TABLE 1.

Characteristics of the included studies.

Gender		The definition of ROP requiring treatmen	Measured outcomes	Mean birth weight (g)	Gestational age (weeks)			Number of participants		Number of eyes		Anti-VEGF dose	Intervention	Author, year
Male	Female			Anti-VEGF	Laser	Anti-VEGF	Anti-VEGF dose	Laser	Anti-VEGF	Laser	Anti-VEGF	Laser
39	40	Zone II (stage 2 or 3 ROP with plus disease).	Recurrence, treatment switch, retreatment, adverse events, and death.	28.37 (±1.96)	1202 (±321)	1133	0.625 mg/0.025 mL	36	43	72	86	28.50 (±1.99)	Intravitreal bevacizumab vs. Laser	Karkhaneh (1)
NR	NR	Zone 1 (stage 3 with/without plus disease).	Structural changes and retinal and choroidal findings on fluorescein angiogram and digital retinal photographs 9 months and 4 years after treatment.	4 infants: mean gestational age = 25.3 (range 22.7-29.3). 17 infants; mean gestational age = 25.6 (range 22.7-29.3).	4 infants: 697 (range 615-755). 17 infants: 667 (range 380-960).	4 infants: 697 (range 615-755). 17 infants: 667 (range 380-960).	0.5mg/0.02mL	21		21	21	4 infants: mean gestational age = 25.3 (range 22.7-29.3). 17 infants; mean gestational age = 25.6 (range 22.7-29.3).	Intravitreal bevacizumab vs. Laser	Lepore (13)
97	53	Zone I or zone II posterior (stage 3 with plus disease).	Recurrence, adverse events, and death.	Zone I ROP: 24.2 Zone II ROP: 24.5	Zone I ROP: 657.9 Zone II ROP: 680.7	Zone I ROP: 615.2 Zone II ROP: 689.2	0.625mg/0.025 mL	75	75	150	150	Zone I ROP: 24.3 Zone II ROP: 24.5	Intravitreal bevacizumab vs. Laser	Mintz-Hittner (3)
NR	NR	Zone I or posterior zone II with plus disease.	Recurrence, treatment switch, retreatment, and death.	Median (range): 25 (24-29)	Median (range): 780 (540-1080)	Median (range): 780 (540-1080)	1.25 mg/0.05mL	15		15	15	Median (range): 25 (24-29)	Intravitreal bevacizumab vs. Laser	O’Keeffe (14)
NR	NR	Zone II (stage 2 or 3 with plus disease).	Regression, treatment switch retreatment, adverse events, and death.	28.75 (±1.86)	1273 (±273)	1232 (±318)	0.625mg/0.025 mL	39	77	78	154	28.32 (±2.11)	Intravitreal bevacizumab vs. Laser	Roohipoor (15)
107	118	Zone I (stage 1, 2 or 3 2 with plus disease), Zone II (stage 3 with plus disease), or aggressive posterior retinopathy of prematurity.	Treatment switch, retreatment, adverse events, and death.	0.1 mg median (range): 26 (23-32) 0.2 mg median (range): 25 (23-32)	831 (±284)	0.1 mg: 886 (±299) 0.2 mg: 791 (±244)	0.1 mg 0.2 mg	74	74	148	148	Median (range): 26 (23-32)	Intravitreal ranibizumab vs. Laser	Stahl (9)
28	22	Zone II (Stage 2 or 3 with plus disease).	Recurrence, treatment switch, retreatment, and adverse events.	28.96 (±1.59)	1.06 (±0.24) (kg)	1.22 (±0.32) (kg)	0.3 mg/0.03 mL	25	75	50	50	28.27 (±1.84)	Intravitreal ranibizumab vs. Laser	Zhang (10)

NR, not reported; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor.